Transgenic mice with liver-targeted overexpression of the secreted EGF fusion protein develop hepatocellular carcinoma, and blockade of EGF receptor activity halt the development and progression of HCC [35-37]. This evidence concerns the gene EGF and hepatocellular carcinoma.